FVIII inhibitors: pathogenesis and avoidance.
(2015) In Blood 125(13). p.2045-2051- Abstract
- The pathogenesis of inhibitory antibodies has been the focus of major scientific interest over the last decades and several studies on underlying immune mechanisms and risk factors for formation of these antibodies have been performed with the aim of improving the ability to both predict and prevent their appearance. It seems clear that the decisive factors for the immune response to the deficient factor are multiple and involve components of both a constitutional and therapy-related nature. A scientific concern and obstacle for research in the area of hemophilia is the relatively small cohorts available for studies and the resulting risk of confounded and biased results. Careful interpretation of data is recommended in order to avoid... (More)
- The pathogenesis of inhibitory antibodies has been the focus of major scientific interest over the last decades and several studies on underlying immune mechanisms and risk factors for formation of these antibodies have been performed with the aim of improving the ability to both predict and prevent their appearance. It seems clear that the decisive factors for the immune response to the deficient factor are multiple and involve components of both a constitutional and therapy-related nature. A scientific concern and obstacle for research in the area of hemophilia is the relatively small cohorts available for studies and the resulting risk of confounded and biased results. Careful interpretation of data is recommended in order to avoid treatment decisions based on a weak scientific platform. This review will summarize current concepts of the underlying immunological mechanisms and risk factors for development of inhibitory antibodies in patients with hemophilia A, and discuss how these findings may be interpreted and influence our clinical management of patients. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5142853
- author
- Astermark, Jan LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 125
- issue
- 13
- pages
- 2045 - 2051
- publisher
- American Society of Hematology
- external identifiers
-
- pmid:25712994
- wos:000354626300009
- scopus:84926155035
- ISSN
- 1528-0020
- DOI
- 10.1182/blood-2014-08-535328
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Faculty of Medicine (000022000), Emergency medicine/Medicine/Surgery (013240200), Clinical Coagulation Research Unit (013242510)
- id
- c6fcfc8e-3bce-4548-ad82-6294ed329a98 (old id 5142853)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25712994?dopt=Abstract
- date added to LUP
- 2016-04-01 10:25:48
- date last changed
- 2022-01-25 23:03:55
@article{c6fcfc8e-3bce-4548-ad82-6294ed329a98,
abstract = {{The pathogenesis of inhibitory antibodies has been the focus of major scientific interest over the last decades and several studies on underlying immune mechanisms and risk factors for formation of these antibodies have been performed with the aim of improving the ability to both predict and prevent their appearance. It seems clear that the decisive factors for the immune response to the deficient factor are multiple and involve components of both a constitutional and therapy-related nature. A scientific concern and obstacle for research in the area of hemophilia is the relatively small cohorts available for studies and the resulting risk of confounded and biased results. Careful interpretation of data is recommended in order to avoid treatment decisions based on a weak scientific platform. This review will summarize current concepts of the underlying immunological mechanisms and risk factors for development of inhibitory antibodies in patients with hemophilia A, and discuss how these findings may be interpreted and influence our clinical management of patients.}},
author = {{Astermark, Jan}},
issn = {{1528-0020}},
language = {{eng}},
number = {{13}},
pages = {{2045--2051}},
publisher = {{American Society of Hematology}},
series = {{Blood}},
title = {{FVIII inhibitors: pathogenesis and avoidance.}},
url = {{http://dx.doi.org/10.1182/blood-2014-08-535328}},
doi = {{10.1182/blood-2014-08-535328}},
volume = {{125}},
year = {{2015}},
}